Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $49.1429.

A number of equities analysts have recently issued reports on the company. Bank of America raised their price target on Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. TD Cowen assumed coverage on Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating on the stock. Wall Street Zen downgraded Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Jefferies Financial Group restated a “hold” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research note on Friday, March 13th.

Insider Transactions at Mineralys Therapeutics

In other news, CEO Jon Congleton sold 75,000 shares of the firm’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $26.27, for a total value of $1,970,250.00. Following the transaction, the chief executive officer directly owned 705,051 shares in the company, valued at $18,521,689.77. This trade represents a 9.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ra Capital Management, L.P. purchased 310,700 shares of the company’s stock in a transaction dated Friday, March 27th. The stock was purchased at an average price of $23.67 per share, for a total transaction of $7,354,269.00. Following the completion of the purchase, the director owned 5,767,221 shares in the company, valued at approximately $136,510,121.07. The trade was a 5.69% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have sold 162,291 shares of company stock valued at $4,336,414. Corporate insiders own 18.94% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of MLYS. Navalign LLC purchased a new position in Mineralys Therapeutics during the fourth quarter valued at $33,000. KBC Group NV bought a new position in shares of Mineralys Therapeutics during the 1st quarter valued at approximately $33,000. Smartleaf Asset Management LLC increased its holdings in Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after acquiring an additional 676 shares in the last quarter. Royal Bank of Canada increased its holdings in Mineralys Therapeutics by 262.3% in the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock worth $56,000 after acquiring an additional 1,107 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in Mineralys Therapeutics by 1,845.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after acquiring an additional 1,993 shares during the period. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Mineralys Therapeutics Trading Up 0.6%

Mineralys Therapeutics stock opened at $29.54 on Tuesday. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -14.41 and a beta of 0.49. The stock has a fifty day simple moving average of $27.15 and a two-hundred day simple moving average of $33.14. Mineralys Therapeutics has a 12 month low of $12.59 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.04. On average, equities research analysts forecast that Mineralys Therapeutics will post -2.29 EPS for the current fiscal year.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Neutral Sentiment: HC Wainwright reiterated a Buy rating and $56 price target on Mineralys Therapeutics, but it lowered earnings estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, FY2029 and FY2030. The revisions suggest more conservative expectations for profitability, which can weigh on sentiment. MarketBeat stock page
• Positive Sentiment: Despite the lower estimates, HC Wainwright still sees long-term upside and maintained its constructive view on the company, signaling that analysts believe Mineralys can still deliver meaningful value over time. MarketBeat stock page
• Negative Sentiment: Wall Street Zen downgraded MLYS to Sell, adding pressure on the shares and likely contributing to the recent weakness in investor sentiment. Article title
• Neutral Sentiment: A separate article highlighted Mineralys Therapeutics’ post-Q1 earnings update and path forward for its lorundrostat NDA, but the headline did not indicate a major new catalyst by itself. Article title

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.